K2 Principal Fund, L.P. I Teos Therapeutics, Inc. Transaction History
K2 Principal Fund, L.P.
- $197 Million
- Q2 2024
A detailed history of K2 Principal Fund, L.P. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 450,000 shares of ITOS stock, worth $4.57 Million. This represents 3.39% of its overall portfolio holdings.
Number of Shares
450,000
Previous 20,000
2150.0%
Holding current value
$4.57 Million
Previous $272,000
2355.15%
% of portfolio
3.39%
Previous 0.1%
Shares
2 transactions
Others Institutions Holding ITOS
# of Institutions
149Shares Held
36.3MCall Options Held
653KPut Options Held
1.48M-
Black Rock Inc. New York, NY3.73MShares$37.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.52MShares$35.7 Million0.79% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.25MShares$33 Million1.7% of portfolio
-
Boxer Capital, LLC San Diego, CA2.95MShares$29.9 Million2.43% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$27.8 Million22.32% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $361M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...